<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184987</url>
  </required_header>
  <id_info>
    <org_study_id>207236</org_study_id>
    <nct_id>NCT03184987</nct_id>
  </id_info>
  <brief_title>A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma</brief_title>
  <official_title>A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>York Bioanalytical Solution</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BI Medical.Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SRL Mediserch.Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel International Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q2 Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite availability of treatments and published guidelines, subjects may have asthma that is
      inadequately controlled. GlaxoSmithKline is currently developing a once-daily 'closed' triple
      therapy of an Inhaled Corticosteroids/Long-Acting Beta-2-Agonists/Long-Acting Muscarinic
      Antagonist (ICS/LAMA/LABA) combination (Fluticasone Furoate/Umeclidinium Bromide/Vilanterol
      Trifenatate [FF/UMEC/VI]) in a single device, with the aim of providing a new treatment
      option for the management of asthma by improving lung function, health-related quality of
      life (HRQoL) and symptom control over established combination therapies. This study has 3
      study periods: Run-in, Treatment period and a Follow-up period. Eligible subjects who meet
      the pre-defined criteria at screening (Visit 1) will enter into a 2-week run-in period.
      Subjects will continue their pre-screening inhaled medications for asthma (ICS+LABA or
      ICS+LABA+LAMA) without any change in regimen/dosage until day before Visit 2. At Visit 2
      subjects will be allocated to either FF/UMEC/VI 100/62.5/25 or FF/UMEC/VI 200/62.5/25
      micrograms (mcg) treatment depending on the asthma control status for 52 weeks. Switching
      medication from FF/UMEC/VI 100/62.5/25 to FF/UMEC/VI 200/62.5/25 will be permitted in
      accordance with the control status of the subject assessed by Asthma Control Questionnaire
      (ACQ)-7 at Week 24 of the treatment period. A follow-up visit will be conducted for
      approximately 1 week. Subjects will be provided with salbutamol as a rescue medication
      throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect, other important medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the outcome mentioned before. Intent-To-Treat (ITT) Population comprised of all participants who received at least one dose of study treatment in the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 12, 24, 36 and 52</time_frame>
    <description>Blood pressure was measured in seated position after 5 minutes rest for participants at indicated time points. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 12, 24, 36 and 52</time_frame>
    <description>Pulse rate was measured in seated position after 5 minutes rest for participants at indicated time points. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR Interval and QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 24 and 52</time_frame>
    <description>Single 12-lead electrocardiograms (ECG) were obtained using an automated ECG machine that measured PR Interval and QTcF Interval. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hematocrit</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hemoglobin</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Platelet Count</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: platelet count. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Basophils/Leukocytes</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: Basophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Eosinophils/Leukocytes</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: Eosinophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Lymphocytes/Leukocytes</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: Lymphocytes/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Monocytes/Leukocytes</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: Monocytes/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Neutrophils/Leukocytes</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the hematology parameter: Neutrophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: alanine aminotransferase, alkaline phosphatase and aspartate aminotransferase. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Albumin, Protein</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: albumin and protein. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Urea</measure>
    <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
    <description>Blood samples were collected to analyze the chemistry parameters: calcium, glucose, potassium, sodium and urea. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Worst Case Post-Baseline Urinalysis Results Relative to Baseline</measure>
    <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    <description>Urine samples were collected for analysis of presence of occult blood and protein in urine using dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of occult blood and protein can be read as Trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>FF/UMEC/VI 100/62.5/25 mcg closed triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF/UMEC/VI 200/62.5/25 mcg closed triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/UMEC/VI 100/62.5/25 mcg</intervention_name>
    <description>Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.</description>
    <arm_group_label>FF/UMEC/VI 100/62.5/25 mcg closed triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/UMEC/VI 200/62.5/25 mcg</intervention_name>
    <description>Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.</description>
    <arm_group_label>FF/UMEC/VI 200/62.5/25 mcg closed triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.</description>
    <arm_group_label>FF/UMEC/VI 100/62.5/25 mcg closed triple therapy</arm_group_label>
    <arm_group_label>FF/UMEC/VI 200/62.5/25 mcg closed triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ACQ-7</intervention_name>
    <description>ACQ-7 will be used for the assessment of control status of asthma.</description>
    <arm_group_label>FF/UMEC/VI 100/62.5/25 mcg closed triple therapy</arm_group_label>
    <arm_group_label>FF/UMEC/VI 200/62.5/25 mcg closed triple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria at the time of informed consent (Visit 0) and at screening (Visit 1).

          -  Age: Participant must be 18 years of age or older at the time of signing the informed
             consent.

          -  Ethnicity: Japanese

          -  Diagnosis: Subjects with a diagnosis of asthma as defined by the National Institutes
             of Health at least one year prior to providing informed consent.

          -  Current Asthma Maintenance Therapy: Outpatients are eligible if they have received
             ICS+LABA or ICS+LABAï¼‹LAMA with asthma control status as Not well controlled with ICS
             (mid-dose) +LABA ; Not well controlled with ICS (high-dose) +LABA or Controlled with
             ICS (mid-dose) +LABA + LAMA; Not well controlled with ICS (mid-dose) +LABA + LAMA;
             Controlled with ICS (high-dose) +LABA + LAMA respectively in stable regimen and dosage
             for at least 4 weeks prior to screening visit (Visit 1) (with medium to high dose of
             ICS defined by the Japanese Guidelines [JGL]). Asthma Control Questionnaire (ACQ-6)
             will be used for the assessment of control status of asthma at Visit 1 (screening
             Visit) (i.e., less than or equal to 0.75 points shows controlled and &gt; 0.75 shows not
             well controlled).

          -  Short-Acting Beta Agonists (SABAs): All subjects must be able to replace their current
             SABA inhaler with salbutamol aerosol inhaler at Visit 1 as needed for the duration of
             the study. Subjects should be able to withhold salbutamol for at least 6 hours prior
             to clinic visit.

          -  Sex: Male and/or female: A female participant is eligible to participate if she is not
             pregnant, not breastfeeding, and at least one of the following conditions applies: Not
             a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the
             contraceptive guidance from the screening visit until after the last dose of study
             medication and completion of the follow-up visit.

          -  Informed Consent: capable of giving signed informed consent which includes compliance
             with the requirements and restrictions listed in the informed consent form (ICF).

        Exclusion Criteria at the time of informed consent (Visit 0) and at screening (Visit 1).

          -  Pneumonia: Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.

          -  Asthma Exacerbation: Any asthma exacerbation requiring a change in maintenance asthma
             therapy in the 6 weeks prior to Visit 1.

          -  COPD: Subjects with the diagnosis of chronic obstructive pulmonary disease, as per
             Global Initiative for Chronic Obstructive Lung Disease (GOLD 2016) guidelines,
             including history of exposure to risk factors (i.e., especially tobacco smoke,
             occupational dusts and chemicals, smoke from home cooking and heating fuels) (for
             tobacco smoke); post- salbutamol Forced Expiratory Volume in 1 second (FEV1)/forced
             vital capacity (FVC) ratio of &lt;0.70 and a post- salbutamol FEV1 of less than or equal
             to 70% of predicted normal values (diagnosis prior to Visit 1 acceptable);Onset of
             disease greater than or equal to 40 years of age.

          -  Concurrent respiratory disorders: Subjects with current evidence of pneumonia, active
             tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis,
             pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
             or abnormalities other than asthma.

          -  Risk Factors for Pneumonia: Immune suppression (e.g., HIV, lupus) or other risk
             factors for pneumonia (e.g., neurological disorders affecting control of the upper
             airway, such as Parkinson's disease, myasthenia gravis). Patients at potentially high
             risk (e.g., very low body mass index (BMI), severely malnourished, or very low FEV1)
             will only be included at the discretion of the Investigator.

          -  Other diseases/abnormalities: Subjects with historical or current evidence of
             clinically significant cardiovascular, neurological, psychiatric, renal, hepatic,
             immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin,
             sensory, endocrine (including uncontrolled diabetes or thyroid disease) or
             hematological abnormalities that are uncontrolled. Significant is defined as any
             disease that, in the opinion of the Investigator, would put the safety of the subject
             at risk through participation, or which would affect the efficacy or safety analysis
             if the disease/condition exacerbated during the study.

          -  Unstable liver disease as defined by the presence of ascites, encephalopathy,
             coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice,
             cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or
             asymptomatic gallstones).Note: Chronic stable hepatitis B and C are acceptable if the
             subject otherwise meets entry criteria.

          -  Clinically significant ECG abnormality: Evidence of a clinically significant
             abnormality in the 12-lead ECG performed during screening. The Investigator will
             determine the clinical significance of each abnormal ECG finding in relation to the
             subject's medical history and exclude subjects who would be at undue risk by
             participating in the trial. An abnormal and clinically significant finding is defined
             as a 12-lead tracing that is interpreted as, but not limited to, any of the following:

               -  Atrial fibrillation (AF) with rapid ventricular rate &gt;120 beats per minute (bpm)

               -  Sustained or nonsustained ventricular tachycardia (VT)

               -  Second degree heart block Mobitz type II and third degree heart block (unless
                  pacemaker or defibrillator had been inserted)

               -  QT interval corrected for heart rate by Fridericia's formula (QTcF) greater than
                  or equal to 500 milliseconds (msec) in patients with QRS &lt;120 msec and QTcF
                  greater than or equal to 530 msec in patients with QRS greater than or equal to
                  120 msec.

          -  Unstable or life threatening cardiac disease: subjects with any of the following at
             screening (Visit 1) would be excluded:

               -  Myocardial infarction or unstable angina in the last 6 months

               -  Unstable or life threatening cardiac arrhythmia requiring intervention in the
                  last 3 months

               -  New York Heart Association (NYHA) Class IV heart failure

          -  Antimuscarinic effects: Subjects with a medical condition such as narrow-angle
             glaucoma, urinary retention, prostatic hypertrophy or bladder neck obstruction should
             only be included if in the opinion of the Investigator the benefit outweighs the risk
             and that the condition would not contraindicate study participation.

          -  Cancer: Subjects with carcinoma that has not been in complete remission for at least 5
             years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma
             and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting
             period if the subject has been considered cured by treatment.

          -  Questionable validity of consent: Subjects with a history of psychiatric disease,
             intellectual deficiency, poor motivation or other conditions that will limit the
             validity of informed consent to participate in the study.

          -  Medication prior to spirometry: Subjects who are medically unable to withhold their
             salbutamol for the 6-hour period required prior to spirometry testing at each study
             visit.

          -  Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug
             abuse within the last 2 years.

          -  Allergy or hypersensitivity: A history of allergy or hypersensitivity to any
             corticosteroid, anticholinergic/muscarinic receptor antagonist, beta-agonist,
             lactose/severe milk protein or magnesium stearate.

          -  Tobacco use: Subjects who are: Current smokers (defined as subjects who have used
             inhaled tobacco products within the 12 months prior to Visit 1 [i.e., cigarettes,
             e-cigarettes/vaping, cigars or pipe tobacco]); Former smokers with a smoking history
             of greater than equal to 10 pack years (e.g., greater than equal to 20 cigarettes/day
             for 10 years).

          -  Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study
             procedures. Any infirmity, disability, or geographic location that would limit
             compliance for scheduled visits.

          -  Affiliation with Investigator site: Study Investigators, sub-Investigators, study
             coordinators, employees of a participating Investigator or study site, or immediate
             family members of the aforementioned that is involved with this study.

          -  Inability to read: In the opinion of the Investigator, any subject who is unable to
             read and/or would not be able to complete study related materials.

        Inclusion Criteria end of the run-in period (Visit 2)

          -  Asthma maintenance therapy: No changes in asthma maintenance therapy (excluding
             salbutamol inhalation aerosol provided at Visit 1) and control status during the
             run-in period. Asthma Control Questionnaire (ACQ-6 at screening and ACQ-7 at the end
             of the run-in period) will be used for the assessment of control status of asthma,
             i.e., 0.75 points shows controlled and &gt;0.75 shows not well controlled.

          -  Concurrent conditions/medical history: Liver function test at Visit1

               -  ALT &lt;2 x upper limit of normal (ULN)

               -  ALP less than or equal to 1.5 x ULN

               -  Bilirubin less than or equal to 1.5 x ULN (isolated bilirubin &gt;1.5 x ULN is
                  acceptable if bilirubin is fractionated and direct bilirubin &lt;35%)

        Exclusion Criteria end of the run-in period (Visit 2)

          -  Respiratory Infection: Occurrence of a culture-documented or suspected bacterial or
             viral infection of the upper or lower respiratory tract, sinus or middle ear during
             the run-in period that led to a change in asthma management or, in the opinion of the
             Investigator, is expected to affect the subject's asthma status or the subject's
             ability to participate in the study.

          -  Severe asthma exacerbation: Evidence of a severe exacerbation during screening or the
             run-in period, defined as deterioration of asthma requiring the use of systemic
             corticosteroids (tablets, suspension, or injection) for at least 3 days or an
             in-patient hospitalization or emergency department visit due to asthma that required
             systemic corticosteroids.

          -  Laboratory test abnormalities: Evidence of clinically significant abnormal laboratory
             tests during screening or the run-in period which are still abnormal upon repeat
             analysis and are not believed to be due to disease(s) present. Each Investigator will
             use his/her own discretion in determining the clinical significance of the
             abnormality.

          -  There is no restriction on diet in this study.

          -  Use of tobacco products will not be allowed from screening until after the final
             follow-up visit. Caffeine and alcohol is allowed ad libitum.

          -  There is no restriction on activity in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>372-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>373-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>732-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>762-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>901-2121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>134-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>157-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toyama</city>
        <zip>937-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>May 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2020</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluticasone furoate</keyword>
  <keyword>fixed dose combination</keyword>
  <keyword>Japanese subjects</keyword>
  <keyword>vilanterol</keyword>
  <keyword>asthma</keyword>
  <keyword>umeclidinium bromide</keyword>
  <keyword>closed triple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03184987/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03184987/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated long-term safety of fixed dose combination therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate (FF/UMEC/VI) in Japanese participants with asthma. The study was conducted across multiple centers in Japan.</recruitment_details>
      <pre_assignment_details>A total of 114 participants were screened, of which 1 failed screening and 2 participants were run-in failures and 111 participants received study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FF/UMEC/VI 100/62.5/25 mcg</title>
          <description>Participants received FF/UMEC/VI 100/62.5/25 microgram (mcg) inhalation powder via ELLIPTA, once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
        </group>
        <group group_id="P2">
          <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
          <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
        </group>
        <group group_id="P3">
          <title>FF/UMEC/VI 200/62.5/25 mcg</title>
          <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FF/UMEC/VI 100/62.5/25 mcg</title>
          <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
        </group>
        <group group_id="B2">
          <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
          <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
        </group>
        <group group_id="B3">
          <title>FF/UMEC/VI 200/62.5/25 mcg</title>
          <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="14.28"/>
                    <measurement group_id="B2" value="48.4" spread="7.76"/>
                    <measurement group_id="B3" value="53.8" spread="12.91"/>
                    <measurement group_id="B4" value="50.9" spread="13.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian-Japanese/East Asian Heritage (EAH)/South EAH</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect, other important medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the outcome mentioned before. Intent-To-Treat (ITT) Population comprised of all participants who received at least one dose of study treatment in the treatment period.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect, other important medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the outcome mentioned before. Intent-To-Treat (ITT) Population comprised of all participants who received at least one dose of study treatment in the treatment period.</description>
          <population>ITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Blood pressure was measured in seated position after 5 minutes rest for participants at indicated time points. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 4, 12, 24, 36 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Blood pressure was measured in seated position after 5 minutes rest for participants at indicated time points. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: Week 4, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="11.27"/>
                    <measurement group_id="O2" value="7.4" spread="9.91"/>
                    <measurement group_id="O3" value="2.7" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="10.35"/>
                    <measurement group_id="O2" value="1.2" spread="12.25"/>
                    <measurement group_id="O3" value="4.6" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="11.68"/>
                    <measurement group_id="O2" value="-1.0" spread="13.87"/>
                    <measurement group_id="O3" value="3.3" spread="12.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Week 36, n=46,8,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="12.60"/>
                    <measurement group_id="O2" value="5.0" spread="15.92"/>
                    <measurement group_id="O3" value="4.6" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="9.21"/>
                    <measurement group_id="O2" value="3.6" spread="9.07"/>
                    <measurement group_id="O3" value="3.4" spread="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 4, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="6.04"/>
                    <measurement group_id="O2" value="3.3" spread="4.64"/>
                    <measurement group_id="O3" value="-0.2" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="9.07"/>
                    <measurement group_id="O2" value="-0.2" spread="7.76"/>
                    <measurement group_id="O3" value="1.7" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="8.32"/>
                    <measurement group_id="O2" value="1.6" spread="5.75"/>
                    <measurement group_id="O3" value="2.1" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 36, n=46,8,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="7.18"/>
                    <measurement group_id="O2" value="4.8" spread="7.40"/>
                    <measurement group_id="O3" value="3.1" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="6.98"/>
                    <measurement group_id="O2" value="2.4" spread="3.70"/>
                    <measurement group_id="O3" value="2.5" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <description>Pulse rate was measured in seated position after 5 minutes rest for participants at indicated time points. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 4, 12, 24, 36 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <description>Pulse rate was measured in seated position after 5 minutes rest for participants at indicated time points. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="9.28"/>
                    <measurement group_id="O2" value="5.9" spread="7.04"/>
                    <measurement group_id="O3" value="1.6" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="9.58"/>
                    <measurement group_id="O2" value="4.4" spread="7.14"/>
                    <measurement group_id="O3" value="2.3" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="8.63"/>
                    <measurement group_id="O2" value="4.6" spread="7.73"/>
                    <measurement group_id="O3" value="-1.8" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=46,8,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="11.65"/>
                    <measurement group_id="O2" value="7.0" spread="9.27"/>
                    <measurement group_id="O3" value="4.2" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.94"/>
                    <measurement group_id="O2" value="-1.4" spread="2.45"/>
                    <measurement group_id="O3" value="1.7" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR Interval and QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)</title>
        <description>Single 12-lead electrocardiograms (ECG) were obtained using an automated ECG machine that measured PR Interval and QTcF Interval. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 4, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR Interval and QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)</title>
          <description>Single 12-lead electrocardiograms (ECG) were obtained using an automated ECG machine that measured PR Interval and QTcF Interval. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Week 4, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="10.12"/>
                    <measurement group_id="O2" value="5.1" spread="10.62"/>
                    <measurement group_id="O3" value="-0.3" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="9.43"/>
                    <measurement group_id="O2" value="-0.4" spread="12.12"/>
                    <measurement group_id="O3" value="2.5" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Week 52, n=46,8,50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="10.11"/>
                    <measurement group_id="O2" value="1.3" spread="9.57"/>
                    <measurement group_id="O3" value="1.7" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Week 4, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.890" spread="11.3898"/>
                    <measurement group_id="O2" value="1.757" spread="13.8084"/>
                    <measurement group_id="O3" value="3.914" spread="27.5206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.577" spread="10.4434"/>
                    <measurement group_id="O2" value="7.578" spread="8.0630"/>
                    <measurement group_id="O3" value="-3.265" spread="14.3663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.745" spread="13.3558"/>
                    <measurement group_id="O2" value="3.243" spread="17.5127"/>
                    <measurement group_id="O3" value="0.969" spread="15.3699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.591"/>
                    <measurement group_id="O2" value="0.49" spread="1.190"/>
                    <measurement group_id="O3" value="0.09" spread="0.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.674"/>
                    <measurement group_id="O2" value="0.76" spread="1.254"/>
                    <measurement group_id="O3" value="0.35" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.915"/>
                    <measurement group_id="O2" value="0.66" spread="1.571"/>
                    <measurement group_id="O3" value="0.22" spread="0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="1.525"/>
                    <measurement group_id="O2" value="0.90" spread="3.240"/>
                    <measurement group_id="O3" value="-0.20" spread="2.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.499"/>
                    <measurement group_id="O2" value="1.49" spread="2.336"/>
                    <measurement group_id="O3" value="0.69" spread="2.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="1.978"/>
                    <measurement group_id="O2" value="1.76" spread="2.753"/>
                    <measurement group_id="O3" value="0.55" spread="2.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.084" spread="0.2046"/>
                    <measurement group_id="O2" value="-0.161" spread="0.2421"/>
                    <measurement group_id="O3" value="-0.056" spread="0.1868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.123" spread="0.1908"/>
                    <measurement group_id="O2" value="-0.109" spread="0.2158"/>
                    <measurement group_id="O3" value="-0.101" spread="0.2114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.1905"/>
                    <measurement group_id="O2" value="-0.055" spread="0.2321"/>
                    <measurement group_id="O3" value="-0.032" spread="0.2026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
        <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
          <description>Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Percentage of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0102" spread="0.01714"/>
                    <measurement group_id="O2" value="-0.0103" spread="0.02148"/>
                    <measurement group_id="O3" value="-0.0061" spread="0.01616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0100" spread="0.01627"/>
                    <measurement group_id="O2" value="-0.0029" spread="0.01527"/>
                    <measurement group_id="O3" value="-0.0063" spread="0.01878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0011" spread="0.01602"/>
                    <measurement group_id="O2" value="0.0034" spread="0.02251"/>
                    <measurement group_id="O3" value="0.0001" spread="0.01749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
        <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
          <description>Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="6.19"/>
                    <measurement group_id="O2" value="-2.4" spread="7.92"/>
                    <measurement group_id="O3" value="-1.3" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="6.33"/>
                    <measurement group_id="O2" value="0.2" spread="6.20"/>
                    <measurement group_id="O3" value="-1.5" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.47"/>
                    <measurement group_id="O2" value="1.4" spread="9.32"/>
                    <measurement group_id="O3" value="0.3" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Platelet Count</title>
        <description>Blood samples were collected to analyze the hematology parameter: platelet count. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Platelet Count</title>
          <description>Blood samples were collected to analyze the hematology parameter: platelet count. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="27.46"/>
                    <measurement group_id="O2" value="-17.7" spread="37.26"/>
                    <measurement group_id="O3" value="4.8" spread="33.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="28.67"/>
                    <measurement group_id="O2" value="-20.6" spread="54.69"/>
                    <measurement group_id="O3" value="4.6" spread="39.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="27.48"/>
                    <measurement group_id="O2" value="-18.4" spread="51.83"/>
                    <measurement group_id="O3" value="3.3" spread="25.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Basophils/Leukocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: Basophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Basophils/Leukocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: Basophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Percentage of basophil in leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.352"/>
                    <measurement group_id="O2" value="-0.03" spread="0.600"/>
                    <measurement group_id="O3" value="-0.10" spread="0.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.334"/>
                    <measurement group_id="O2" value="-0.03" spread="0.487"/>
                    <measurement group_id="O3" value="-0.05" spread="0.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.373"/>
                    <measurement group_id="O2" value="0.01" spread="0.295"/>
                    <measurement group_id="O3" value="0.05" spread="0.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Eosinophils/Leukocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: Eosinophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Eosinophils/Leukocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: Eosinophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Percentage of eosinophils in leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="2.140"/>
                    <measurement group_id="O2" value="-0.18" spread="3.500"/>
                    <measurement group_id="O3" value="-0.87" spread="3.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="2.694"/>
                    <measurement group_id="O2" value="1.68" spread="2.859"/>
                    <measurement group_id="O3" value="0.19" spread="3.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="2.924"/>
                    <measurement group_id="O2" value="0.01" spread="5.046"/>
                    <measurement group_id="O3" value="0.13" spread="4.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Lymphocytes/Leukocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: Lymphocytes/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Lymphocytes/Leukocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: Lymphocytes/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Percentage of lymphocytes in leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="7.644"/>
                    <measurement group_id="O2" value="-0.12" spread="6.009"/>
                    <measurement group_id="O3" value="-0.95" spread="6.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="5.431"/>
                    <measurement group_id="O2" value="-3.20" spread="6.279"/>
                    <measurement group_id="O3" value="-2.06" spread="5.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="5.198"/>
                    <measurement group_id="O2" value="-0.07" spread="7.054"/>
                    <measurement group_id="O3" value="-1.54" spread="5.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Monocytes/Leukocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: Monocytes/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Monocytes/Leukocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: Monocytes/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Percentage of monocytes in leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.717"/>
                    <measurement group_id="O2" value="0.03" spread="1.141"/>
                    <measurement group_id="O3" value="-0.34" spread="1.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="1.518"/>
                    <measurement group_id="O2" value="0.20" spread="1.683"/>
                    <measurement group_id="O3" value="0.17" spread="1.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="1.400"/>
                    <measurement group_id="O2" value="-0.19" spread="1.174"/>
                    <measurement group_id="O3" value="-0.04" spread="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Neutrophils/Leukocytes</title>
        <description>Blood samples were collected to analyze the hematology parameter: Neutrophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Neutrophils/Leukocytes</title>
          <description>Blood samples were collected to analyze the hematology parameter: Neutrophils/Leukocytes. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Percentage of neutrophils in leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="8.777"/>
                    <measurement group_id="O2" value="0.30" spread="7.925"/>
                    <measurement group_id="O3" value="2.26" spread="8.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="6.599"/>
                    <measurement group_id="O2" value="1.36" spread="9.352"/>
                    <measurement group_id="O3" value="1.76" spread="7.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="6.487"/>
                    <measurement group_id="O2" value="0.24" spread="8.451"/>
                    <measurement group_id="O3" value="1.40" spread="7.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase</title>
        <description>Blood samples were collected to analyze the chemistry parameters: alanine aminotransferase, alkaline phosphatase and aspartate aminotransferase. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase</title>
          <description>Blood samples were collected to analyze the chemistry parameters: alanine aminotransferase, alkaline phosphatase and aspartate aminotransferase. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="8.56"/>
                    <measurement group_id="O2" value="-2.1" spread="6.51"/>
                    <measurement group_id="O3" value="-1.5" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="8.62"/>
                    <measurement group_id="O2" value="-0.4" spread="4.50"/>
                    <measurement group_id="O3" value="0.3" spread="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="10.07"/>
                    <measurement group_id="O2" value="-1.1" spread="4.49"/>
                    <measurement group_id="O3" value="1.4" spread="22.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="22.83"/>
                    <measurement group_id="O2" value="2.0" spread="14.56"/>
                    <measurement group_id="O3" value="-13.2" spread="36.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="20.89"/>
                    <measurement group_id="O2" value="2.6" spread="30.69"/>
                    <measurement group_id="O3" value="-8.1" spread="41.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="26.70"/>
                    <measurement group_id="O2" value="-7.9" spread="31.86"/>
                    <measurement group_id="O3" value="-7.2" spread="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="8.05"/>
                    <measurement group_id="O2" value="-0.6" spread="2.70"/>
                    <measurement group_id="O3" value="-1.3" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="8.10"/>
                    <measurement group_id="O2" value="0.6" spread="2.46"/>
                    <measurement group_id="O3" value="-0.0" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="9.80"/>
                    <measurement group_id="O2" value="0.3" spread="3.15"/>
                    <measurement group_id="O3" value="0.6" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Albumin, Protein</title>
        <description>Blood samples were collected to analyze the chemistry parameters: albumin and protein. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Albumin, Protein</title>
          <description>Blood samples were collected to analyze the chemistry parameters: albumin and protein. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.60"/>
                    <measurement group_id="O2" value="0.4" spread="4.10"/>
                    <measurement group_id="O3" value="0.1" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.02"/>
                    <measurement group_id="O2" value="-0.1" spread="5.53"/>
                    <measurement group_id="O3" value="-0.3" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.27"/>
                    <measurement group_id="O2" value="-0.9" spread="3.80"/>
                    <measurement group_id="O3" value="-0.6" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.06"/>
                    <measurement group_id="O2" value="-0.1" spread="3.79"/>
                    <measurement group_id="O3" value="-0.1" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.59"/>
                    <measurement group_id="O2" value="-0.7" spread="3.71"/>
                    <measurement group_id="O3" value="-0.8" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.12"/>
                    <measurement group_id="O2" value="-1.4" spread="4.07"/>
                    <measurement group_id="O3" value="-0.7" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin</title>
        <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin</title>
          <description>Blood samples were collected to analyze the chemistry parameters: bilirubin, creatinine and direct bilirubin. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.764" spread="3.5263"/>
                    <measurement group_id="O2" value="2.850" spread="2.7037"/>
                    <measurement group_id="O3" value="1.213" spread="3.0103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.967" spread="2.8535"/>
                    <measurement group_id="O2" value="3.040" spread="3.8024"/>
                    <measurement group_id="O3" value="-0.230" spread="4.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.223" spread="3.0718"/>
                    <measurement group_id="O2" value="2.779" spread="1.8137"/>
                    <measurement group_id="O3" value="0.000" spread="3.2445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3762" spread="5.16031"/>
                    <measurement group_id="O2" value="0.3929" spread="7.64431"/>
                    <measurement group_id="O3" value="1.2697" spread="6.83001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1139" spread="4.90769"/>
                    <measurement group_id="O2" value="-0.4911" spread="5.04173"/>
                    <measurement group_id="O3" value="0.9860" spread="5.01490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6918" spread="4.88441"/>
                    <measurement group_id="O2" value="-0.7735" spread="4.85194"/>
                    <measurement group_id="O3" value="0.9533" spread="5.52579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.182" spread="1.4366"/>
                    <measurement group_id="O2" value="0.950" spread="0.9012"/>
                    <measurement group_id="O3" value="0.155" spread="1.2433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.149" spread="0.8701"/>
                    <measurement group_id="O2" value="1.140" spread="1.2092"/>
                    <measurement group_id="O3" value="-0.329" spread="1.3561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.223" spread="1.3299"/>
                    <measurement group_id="O2" value="0.641" spread="0.8850"/>
                    <measurement group_id="O3" value="-0.101" spread="1.1035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Urea</title>
        <description>Blood samples were collected to analyze the chemistry parameters: calcium, glucose, potassium, sodium and urea. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1), Weeks 12, 24 and 52</time_frame>
        <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Urea</title>
          <description>Blood samples were collected to analyze the chemistry parameters: calcium, glucose, potassium, sodium and urea. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated as relevant visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0021" spread="0.07464"/>
                    <measurement group_id="O2" value="-0.0083" spread="0.08461"/>
                    <measurement group_id="O3" value="-0.0245" spread="0.23525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0016" spread="0.06805"/>
                    <measurement group_id="O2" value="-0.0055" spread="0.12399"/>
                    <measurement group_id="O3" value="0.0043" spread="0.07586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0125" spread="0.07815"/>
                    <measurement group_id="O2" value="0.0000" spread="0.09335"/>
                    <measurement group_id="O3" value="0.0313" spread="0.06560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0343" spread="0.90775"/>
                    <measurement group_id="O2" value="-0.0370" spread="0.58286"/>
                    <measurement group_id="O3" value="0.1605" spread="0.82194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1255" spread="0.68761"/>
                    <measurement group_id="O2" value="0.0247" spread="0.40136"/>
                    <measurement group_id="O3" value="0.2701" spread="0.79361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0567" spread="0.78708"/>
                    <measurement group_id="O2" value="0.1804" spread="0.46514"/>
                    <measurement group_id="O3" value="0.1099" spread="0.66570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.326"/>
                    <measurement group_id="O2" value="-0.07" spread="0.206"/>
                    <measurement group_id="O3" value="-0.04" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.308"/>
                    <measurement group_id="O2" value="0.07" spread="0.357"/>
                    <measurement group_id="O3" value="-0.06" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.293"/>
                    <measurement group_id="O2" value="0.04" spread="0.346"/>
                    <measurement group_id="O3" value="0.03" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.77"/>
                    <measurement group_id="O2" value="-0.3" spread="2.00"/>
                    <measurement group_id="O3" value="-0.1" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.81"/>
                    <measurement group_id="O2" value="-1.0" spread="1.80"/>
                    <measurement group_id="O3" value="-0.3" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.13"/>
                    <measurement group_id="O2" value="-0.8" spread="1.83"/>
                    <measurement group_id="O3" value="-0.2" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea: Week 12, n=47,9,55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1162" spread="1.16663"/>
                    <measurement group_id="O2" value="-0.9282" spread="1.68737"/>
                    <measurement group_id="O3" value="0.1889" spread="1.26748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea: Week 24, n=46,9,52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5301" spread="1.16959"/>
                    <measurement group_id="O2" value="-1.3328" spread="1.64540"/>
                    <measurement group_id="O3" value="-0.2018" spread="1.01357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea: Week 52, n=46,8,51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2398" spread="1.50149"/>
                    <measurement group_id="O2" value="-0.4641" spread="1.28392"/>
                    <measurement group_id="O3" value="-0.0224" spread="1.17972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Worst Case Post-Baseline Urinalysis Results Relative to Baseline</title>
        <description>Urine samples were collected for analysis of presence of occult blood and protein in urine using dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of occult blood and protein can be read as Trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
        <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI 100/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
          <group group_id="O3">
            <title>FF/UMEC/VI 200/62.5/25 mcg</title>
            <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Post-Baseline Urinalysis Results Relative to Baseline</title>
          <description>Urine samples were collected for analysis of presence of occult blood and protein in urine using dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of occult blood and protein can be read as Trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Baseline is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.</description>
          <population>ITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occult Blood; No Change/Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood; Increase to Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood; Increase to 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood; Increase to 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood; Increase to 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; No Change/Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Increase to Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Increase to 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Increase to 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; Increase to 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-SAEs and SAEs were collected from Day 1 up to Week 52</time_frame>
      <desc>ITT Population comprised of all participants who received at least one dose of study treatment in the treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>FF/UMEC/VI 100/62.5/25 mcg</title>
          <description>Participants received FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants received salbutamol via metered-dose inhaler as a rescue medication during the study.</description>
        </group>
        <group group_id="E2">
          <title>FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg</title>
          <description>Participants were administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning for 24 weeks. Participants with inadequate asthma control as assessed by Asthma Control Questionnaire-7 (ACQ-7) (i.e. ACQ score &gt;0.75) could be switched treatment from FF/UMEC/VI 100/62.5/25 mcg to FF/UMEC/VI 200/62.5/25 mcg at Week 24 of the treatment period based on the ACQ-7. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
        </group>
        <group group_id="E3">
          <title>FF/UMEC/VI 200/62.5/25 mcg</title>
          <description>Participants received FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA once daily in the morning for 52 weeks. Participants were administered salbutamol via metered-dose inhaler as a rescue medication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilic granulomatosis with polyangiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

